Consistency of Serial CSF alpha-Synuclein Seed Amplification Assay Results in the Parkinson's Progression Marker Initiative

This study demonstrates that serial cerebrospinal fluid alpha-synuclein seed amplification assay results exhibit high intra-individual consistency over time across Parkinson's disease, prodromal, and healthy control participants in the Parkinson's Progression Marker Initiative.

The Gist

The Big Picture: Checking the "Smoke Detector" Over Time

Imagine you have a very sophisticated smoke detector installed in your house. This isn't a normal detector; it's designed to sniff out a specific type of invisible smoke called alpha-synuclein. In the world of Parkinson's disease, this "smoke" is a sign that the disease is present in the brain.

For a long time, scientists have known this detector works great. But a big question remained: If you check the detector today, and then check it again two years from now, will it give you the same reading?

Will the smoke suddenly appear out of nowhere? Or will the "clean air" reading suddenly turn into a "smoke" reading? Or, perhaps more worryingly, will the detector start glitching and give you a different answer just because it's a different day?

This study, involving over 1,200 people in the Parkinson's Progression Marker Initiative (PPMI), set out to answer that question. They wanted to know if this "smoke detector" (the test) is consistent over time.

The Experiment: A Long-Term Check-Up

Think of the study participants as three different groups of people living in different neighborhoods:

1. The "Parkinson's" Neighborhood: People who already have a confirmed diagnosis of Parkinson's.
2. The "Prodromal" Neighborhood: People who have early warning signs (like losing their sense of smell or having weird sleep behaviors) but haven't been diagnosed with Parkinson's yet. They are on the "edge."
3. The "Healthy" Neighborhood: People with no signs of Parkinson's at all.

The researchers took a sample of fluid from the spinal cord (CSF) from these people. This is like taking a tiny air sample from the house to test the smoke detector. They didn't just do this once; they did it multiple times over several years (a median of 2 years, with some people followed for up to 11 years).

The Results: The Detector is Rock-Solid

The findings were incredibly reassuring. The "smoke detector" was almost never wrong when checked twice.

• If the test said "Smoke" (Positive) today:

  • 96% of people with Parkinson's who tested positive stayed positive later.
  • 99% of people in the "early warning" group who tested positive stayed positive.
  • 89% of healthy people who surprisingly tested positive stayed positive.
  • The Analogy: If the detector beeps today, it's almost guaranteed to still be beeping two years from now. The "smoke" doesn't just vanish.

• If the test said "Clean Air" (Negative) today:

  • 92% of people with Parkinson's who tested negative stayed negative.
  • 95% of the "early warning" group stayed negative.
  • 87% of healthy people stayed negative.
  • The Analogy: If the detector is silent today, it will almost certainly stay silent later. The "smoke" doesn't just magically appear out of nowhere.

The "Glitch" Rate is Tiny

In the "early warning" group (prodromal), a very small number of people (about 2%) went from "Clean Air" to "Smoke" over time.

• The Analogy: This is like a house that was perfectly safe for years, and then, slowly over time, a tiny fire started. This is actually good news for the test! It means the test is sensitive enough to catch the disease before the patient even feels sick. It's not a glitch; it's the test doing its job by spotting the disease as it progresses.

Why Does This Matter?

Before this study, doctors and researchers were a little nervous. They wondered: "Do we need to test these patients every six months to make sure the result hasn't changed? Is the test unreliable?"

This study says: No.

• For Patients: You likely only need this test once to know your status for at least two years. You don't need to undergo the procedure repeatedly just to double-check.
• For Clinical Trials: If a new drug is being tested, researchers can trust that a single test result is a reliable baseline. They don't need to worry that the test results will flip-flop randomly.
• For the "Glitchy" Cases: Even in the rare cases where a healthy person tested positive or a Parkinson's patient tested negative, the results were still consistent over time. The test didn't just randomly change its mind.

The Bottom Line

Think of this alpha-synuclein test as a highly reliable weather forecast. If the forecast says "Sunny" today, it's safe to assume it will be sunny for the next few years. If it says "Stormy," the storm isn't going to clear up overnight.

This research confirms that the test is stable, trustworthy, and consistent. It gives doctors and patients confidence that a single test result is a solid foundation for understanding Parkinson's disease, without needing to constantly re-test to see if the answer has changed.

Technical Summary

1. Problem Statement

While alpha-synuclein seed amplification assays (aSyn-SAA) performed on cerebrospinal fluid (CSF) have demonstrated high sensitivity and specificity for detecting alpha-synuclein (aSyn) pathology in Parkinson's disease (PD), dementia with Lewy bodies (DLB), and prodromal states, most existing data are cross-sectional.

• The Gap: There is a lack of longitudinal data regarding the intra-individual consistency of aSyn-SAA results over time.
• The Need: As aSyn-SAA becomes integrated into clinical trials and potential diagnostic workflows, it is critical to determine if a single test result remains stable over time or if frequent re-testing is required to confirm biomarker status.
• Specific Questions: The study aimed to evaluate consistency in:
  1. Typical results (aSyn-SAA+ PD, aSyn-SAA- Healthy Controls).
  2. Infrequent/Unexpected results (aSyn-SAA- PD, aSyn-SAA+ Healthy Controls).
  3. Prodromal states where a shift from negative to positive might indicate disease progression.

2. Methodology

Study Cohort & Design

• Source: Data was drawn from the Parkinson's Progression Marker Initiative (PPMI), a large, international, public-private observational study.
• Participants: 1,238 individuals with more than one CSF aSyn-SAA result were analyzed.
  • Parkinson's Disease (PD): 633 participants (including sporadic PD and those with pathogenic genetic variants like LRRK2, GBA1, SNCA, PRKN).
  • Prodromal: 563 participants (including idiopathic REM sleep behavior disorder [iRBD], hyposmia, and non-manifesting genetic carriers).
  • Healthy Controls (HC): 42 participants.
• Follow-up Duration: Samples were collected over a median of 2.0 years (range: 0.4 to 11.4 years).
• Sampling: A total of 2,738 CSF aSyn-SAA results were analyzed (median 2 samples per participant).

Assay Protocol

• Testing Facility: All assays were performed by Amprion (San Diego, CA) by staff blinded to clinical diagnoses.
• Assay Versions: The study utilized three versions of the assay over time:
  • 150-hour (h) version.
  • 24-hour (h) version.
  • 35-hour (h) version.
• Differentiation: The 24h and 35h assays could distinguish between Type-I seeding (associated with PD/DLB) and Type-II seeding (associated with Multiple System Atrophy).
• Data Handling: If a participant had multiple assay versions run at a single visit, the most recent result was used.

Statistical Analysis

• Consistency rates were calculated using point estimates and 95% Wilson confidence intervals.
• Analysis was stratified by cohort (PD, Prodromal, HC) and initial result status (Positive vs. Negative).

3. Key Contributions

• First Large-Scale Longitudinal Analysis: This is the first study to report longitudinal consistency of aSyn-SAA in a large, deeply phenotyped cohort of sporadic PD and prodromal participants without pathogenic variants.
• Validation of Rare Phenotypes: It specifically addresses the stability of results in "edge cases" (e.g., PD patients who test negative, or healthy controls who test positive), which are critical for understanding assay specificity and sensitivity limits.
• Assay Version Comparison: It provides empirical evidence that results from the newer, faster assays (24h/35h) are highly consistent with the older, longer-duration 150h assay.

4. Key Results

Overall Consistency Rates
The study found high intra-individual consistency across all groups over the median 2-year follow-up:

Cohort	Initial Status	Consistency Rate (Remained Same)	95% CI
PD	aSyn-SAA Positive	96% (474/493)	94–98%
PD	aSyn-SAA Negative	92% (116/126)	86–96%
Prodromal	aSyn-SAA Positive	99% (303/307)	97–99%
Prodromal	aSyn-SAA Negative	95% (234/247)	91–97%
Healthy Control	aSyn-SAA Positive	89% (16/18)	67–97%
Healthy Control	aSyn-SAA Negative	87% (20/23)	68–95%

Conversion Rates (Prodromal Group)

• Negative to Positive: 2% (11/563) of prodromal participants with initial negative results converted to positive.
• Time to Conversion: The median time to conversion was 2.4 years (range 1.1–5.5 years), suggesting these conversions likely reflect genuine disease progression rather than assay error.

Assay Version Consistency

• Among 523 participants tested with different assay versions (150h vs. 24h/35h) at different time points, 96% had consistent results.
• When excluding the 150h assay data, 98% of initially Type-I positive participants remained positive, and 90% of initially negative participants remained negative.

5. Significance and Implications

• Clinical Utility: The results strongly suggest that a single CSF aSyn-SAA test is likely sufficient to characterize a participant's aSyn biomarker profile for at least a two-year period. Frequent re-testing to "confirm" a result is likely unnecessary for typical cases.
• Reliability in Edge Cases: The high consistency even in unexpected results (e.g., aSyn-SAA- PD or aSyn-SAA+ HC) reinforces the robustness of the assay and suggests that discordant results are rare and likely biological rather than technical artifacts.
• Disease Progression Marker: The low conversion rate (2%) in prodromal participants over ~2 years indicates that aSyn-SAA positivity is a stable marker of established pathology, and conversion is a slow process. This supports the use of aSyn-SAA as a stratification tool in clinical trials.
• Assay Evolution: The study validates the transition from the 150h assay to the faster 24h/35h versions, confirming that the newer, more efficient assays do not compromise longitudinal data integrity.

Limitations Noted by Authors

• The study used three different assay versions, which may have slightly lowered the estimated consistency rates compared to a single-version study.
• The number of participants with Type-II seeding or inconclusive results was too small for robust statistical comparison.
• Long-term follow-up (>2 years) for prodromal conversion is ongoing.

Conclusion
This study provides critical validation for the use of CSF aSyn-SAA in longitudinal settings, confirming that the assay yields highly stable results over time across diverse clinical populations, thereby supporting its integration into clinical trials and future diagnostic workflows.